

Draft Proposal for Comments and Inclusion in The Indian Pharmacopoeia

Lactulose Concentrate

Published on: 18.08.2023

Last date for comments: 02.10.2023

This draft proposal contains monograph text for inclusion in the Indian Pharmacopoeia (IP). The content of this draft document is not final, and the text may be subject to revisions before publication in the IP. This draft does not necessarily represent the decisions or the stated policy of the IP or Indian Pharmacopoeia Commission (IPC).


Manufacturers, regulatory authorities, health authorities, researchers, and other stakeholders are invited to provide their feedback and comments on this draft proposal. Manufacturers are also invited to submit samples of their products to the IPC to ensure that the proposed monograph adequately controls the quality of the product(s) they manufacture. Comments and samples received after the last date will not be considered by the IPC before finalizing the monograph.

Please send any comments you may have on this draft document to lab.ipc@gov.in, with a copy to Dr. Gaurav Pratap Singh (email: gpsingh.ipc@gov.in) before the last date for comments.

Document History and Schedule for the Adoption Process

Description	Details
Document version	1.0
Monograph proposed for inclusion	IP Addendum 2024
Tentative effective date of monograph	April, 2024
First draft published on IPC website for public comments	18.08.2023
Draft revision published on IPC website for public comments	
Further follow-up action as required.	

Lactulose Concentrate



$C_{12}H_{22}O_{11}$

Mol. Wt. 342.3

Lactulose Concentrate is D-Fructose, 4-O-β-D-galactopyranosyl.

Lactulose Concentrate is a solution of sugars prepared from Lactose. It consists principally of lactulose together with minor quantities of lactose and galactose, and traces of other related sugars and water.

Lactulose Concentrate contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of lactulose $C_{12}H_{22}O_{11}$. It contains no added substances.

Category. Laxative, Ammonium Dextroicants.

Description. A colorless to amber syrupy liquid; which may exhibit some precipitation and darkening upon standing

Identification

A. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (b).

B. Dilute 0.5 ml of the concentrate with 10 ml of water. Add 5 ml of hot alkaline cupric-tartaric solution. A red precipitate of cuprous oxide is formed.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dilute a quantity of concentrate containing 2.0 g of Lactulose in 20 ml of water, add 25.0 ml of acetonitrile, allow the solution to reach at room temperature and dilute to 50.0 ml with water.

Reference solution (a). A solution containing 0.64 per cent w/v of galactose IPRS, 0.48 per cent w/v of anhydrous lactose IPRS, 0.32 per cent w/v of epilactose IPRS, 0.12 per cent w/v of tagatose IPRS and 0.04 per cent w/v of fructose IPRS in a mixture of equal volumes of acetonitrile and water.

Reference solution (b). A solution containing 4.0 per cent w/v of lactulose IPRS, 0.48 per cent w/v of anhydrous lactose IPRS and 0.32 per cent w/v of epilactose IPRS in a mixture of equal volumes of acetonitrile and water.

Chromatographic system

- a stainless steel column 15 cm x 4.6 mm, packed with aminopropylsilane bonded to porous silica (3 μm), (Such as Hypersil APS-2),
- column temperature: 40°,
- mobile phase: a mixture of 18 volumes of a buffer solution prepared by dissolving 1.15 g of sodium dihydrogen phosphate in 1000 ml of water and 82 volumes of acetonitrile, (Note-Adjust the concentration of acetonitrile between 78 per cent and 85 per cent to obtain appropriate retention times),
- flow rate: 1.3 ml per minute,

- refractometer maintained at 40°,
- injection volume: 20 µl.

Name	Relative retention time
Tagatose	0.30
Fructose	0.34
Galactose	0.47
Epilactose	0.90
Lactulose	1.00
Lactose	1.17

Inject reference solution (b). The test is not valid unless the resolution between the peaks due to lactulose and lactose is not less than 1.5, between the peaks due to lactulose and epilactose is not less than 0.9 and the relative standard deviation for replicate injections is not more than 2.0 per cent for lactulose peak.

Inject reference solution (a) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to tagatose is not more than 1.33 times the area of the corresponding peak in the chromatogram obtained with reference solution (a) (4.0 per cent), the area of any peak corresponding to fructose is not more than the area of the corresponding peak in the chromatogram obtained with reference solution (a) (1.0 per cent), the area of any peak corresponding to galactose is not more than the area of the corresponding peak in the chromatogram obtained with reference solution (a) (16.0 per cent), the area of any peak corresponding to epilactose is not more than the area of the corresponding peak in chromatogram obtained with reference solution (a) (8.0 per cent) and the area of any peak corresponding to lactose is not more than the area of the corresponding peak in chromatogram obtained with reference solution (a) (12.0 per cent).

Heavy metals (2.3.13). 1.0 g complies with limit test for heavy metals, Method B (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Assay. Determine by liquid chromatography (2.4.14), as described under Related substances.

Injection reference solution (b) and the test solution.

Calculate the content of C₁₂H₂₂O₁₁.

Storage. Store preferably at a temperature between 2⁰ and 30⁰, avoid subfreezing temperatures.

Labelling. The label states that this article is not intended for direct administration to humans or animals.

Solubility (2.4.26). Miscible with *water*.